RT Journal Article
T1 Small-molecule theranostics in Alzheimer's disease
A1 Sarabia Vallejo, Álvaro
A1 López-Alvarado Gutiérrez, María Pilar
A1 Menéndez Ramos, José Carlos
AB Alzheimer's Disease (AD) remains one of the most challenging health-related issues for our society. It is becoming increasingly prevalent, especially in developed countries, due to the rising life expectancy and, moreover, represents a considerable economic burden worldwide. All efforts at the discovery of new diagnostic and therapeutic tools in the last decades have invariably met with failure, making AD an incurable illness and underscoring the need for new approaches. In recent years, theranostic agents have emerged as an interesting strategy. They are molecules able to simultaneously provide diagnostic information and deliver therapeutic activity, allowing for the assessment of the molecule activity, the organism response and the pharmacokinetics. This makes these compounds promising for streamlining research on AD drugs and for their application in personalized medicine. We review here the field of small-molecule theranostic agents as promising tools for the development of novel diagnostic and therapeutic resources against AD, highlighting the positive and significant impact that theranostics can be expected to have in the near future in clinical practice.
PB Elsevier
SN 0223-5234
YR 2023
FD 2023-07-05
LK https://hdl.handle.net/20.500.14352/112062
UL https://hdl.handle.net/20.500.14352/112062
LA eng
NO Álvaro Sarabia-Vallejo, Pilar López-Alvarado, J. Carlos Menéndez, Small-molecule theranostics in Alzheimer's disease, European Journal of Medicinal Chemistry, Volume 255, 2023, 115382, https://doi.org/10.1016/j.ejmech.2023.115382.
NO 2023 Acuerdos transformativos CRUE
NO Ministerio de Ciencia e Innovación (España)
DS Docta Complutense
RD 8 abr 2025